{"DataElement":{"publicId":"7477457","version":"1","preferredName":"Gene Therapy Administered Product Name","preferredDefinition":"A description of the gene product that was administered.","longName":"3637771v1.0:7477455v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"3637771","version":"1","preferredName":"Gene Therapy Administered","preferredDefinition":"Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or an acquired disease such as cancer.  The genetic material as 'naked' DNA can be delivered into the cells alone or can be delivered into cells by different types of vectors such as viruses which may contain DNA or RNA.  Gene therapy techniques attempt to replace a faulty/missing gene associated with a particular disease, mediate localized delivery of a protein producing specified therapeutic effects, or introduce new cellular functions.  Gene therapies are designed to deliver genetic material into somatic cells and not germ cells, so that only cells of patients and not those of their offspring contain and express the genetic material delivered. (NCI04)_The act of having given something (e.g., a medication or test).","longName":"3637769v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"3637769","version":"1","preferredName":"Gene Therapy","preferredDefinition":"Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or an acquired disease such as cancer.  The genetic material as 'naked' DNA can be delivered into the cells alone or can be delivered into cells by different types of vectors such as viruses which may contain DNA or RNA.  Gene therapy techniques attempt to replace a faulty/missing gene associated with a particular disease, mediate localized delivery of a protein producing specified therapeutic effects, or introduce new cellular functions.  Gene therapies are designed to deliver genetic material into somatic cells and not germ cells, so that only cells of patients and not those of their offspring contain and express the genetic material delivered. (NCI04)","longName":"C15238","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gene Therapy","conceptCode":"C15238","definition":"Application of genetic material (usually DNA) into cells in order to permanently correct an inherited disease or acquired disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D00DDC54-025B-EE7F-E040-BB89AD4305D6","latestVersionIndicator":"Yes","beginDate":"2012-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-12-04","modifiedBy":"ONEDATA","dateModified":"2012-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D00DDC54-0269-EE7F-E040-BB89AD4305D6","latestVersionIndicator":"Yes","beginDate":"2012-12-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2012-12-04","modifiedBy":"KUMMEROA","dateModified":"2018-08-15","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7477455","version":"1","preferredName":"Gene Product Name","preferredDefinition":"A protein, RNA or a complex that contains proteins and/or RNA._The words or language units by which a thing is known.","longName":"7477455v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other name","valueDescription":"Other Name Gene Product","ValueMeaning":{"publicId":"7546404","version":"1","preferredName":"Other Name Gene Product","longName":"7546404","preferredDefinition":"Different than the one(s) previously specified or mentioned.: The words or language units by which a thing is known.: A protein, RNA or a complex that contains proteins and/or RNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Gene Product","conceptCode":"C26548","definition":"A protein, RNA or a complex that contains proteins and/or RNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8A75E8C-4303-5560-E053-4EBD850AE7EE","latestVersionIndicator":"Yes","beginDate":"2021-01-11","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-01-11","modifiedBy":"ONEDATA","dateModified":"2021-01-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8A75E8C-431E-5560-E053-4EBD850AE7EE","beginDate":"2020-10-23","endDate":null,"createdBy":"MALUMK","dateCreated":"2021-01-11","modifiedBy":"ONEDATA","dateModified":"2021-01-11","deletedIndicator":"No"},{"value":"Exagamglogene autotemcel","valueDescription":null,"ValueMeaning":{"publicId":"13571196","version":"1","preferredName":"Exagamglogene Autotemcel","longName":"13571196v1.00","preferredDefinition":"A population of autologous cluster of differentiation 34 (CD34)-positive human hematopoietic stem and progenitor cells (hHSPCs) that are ex-vivo gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex at the erythroid lineage-specific enhancer of the B-cell lymphoma/leukemia 11A (BCL11A) gene, with potential usage for transplantation in patients with sickle cell disease (SCD) and beta-thalassemia. CD34-positive HSPCs are isolated from human blood upon apheresis and are genetically modified in vitro using CRISPR/Cas9 technology to specifically disrupt the erythroid enhancer of the BCL11A gene. As BCL11A is a suppressor of fetal hemoglobin (HbF; hemoglobin F) expression, disruption of the BCL11A enhancer decreases the expression of BCL11A and stimulates the expression of HbF in erythrocytes that differentiate from CTX001. Upon infusion back into the patient following myeloablative, conditioning chemotherapy, exagamglogene autotemcel can populate the bone marrow and differentiate into a variety of blood cell types including lymphoid cells, myeloid cells and erythroblasts. The increased production of high levels of HbF in red blood cells (RBCs) compensates for the defective or reduced adult hemoglobin (Hb) in patients with SCD and beta-thalassemia. HbF is a form of the oxygen carrying Hb that is naturally present at birth and is then replaced by the adult form of hemoglobin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Exagamglogene Autotemcel","conceptCode":"C169042","definition":"A population of autologous cluster of differentiation 34 (CD34)-positive human hematopoietic stem and progenitor cells (hHSPCs) that are ex-vivo gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex at the erythroid lineage-specific enhancer of the B-cell lymphoma/leukemia 11A (BCL11A) gene, with potential usage for transplantation in patients with sickle cell disease (SCD) and beta-thalassemia. CD34-positive HSPCs are isolated from human blood upon apheresis and are genetically modified in vitro using CRISPR/Cas9 technology to specifically disrupt the erythroid enhancer of the BCL11A gene. As BCL11A is a suppressor of fetal hemoglobin (HbF; hemoglobin F) expression, disruption of the BCL11A enhancer decreases the expression of BCL11A and stimulates the expression of HbF in erythrocytes that differentiate from CTX001. Upon infusion back into the patient following myeloablative, conditioning chemotherapy, exagamglogene autotemcel can populate the bone marrow and differentiate into a variety of blood cell types including lymphoid cells, myeloid cells and erythroblasts. The increased production of high levels of HbF in red blood cells (RBCs) compensates for the defective or reduced adult hemoglobin (Hb) in patients with SCD and beta-thalassemia. HbF is a form of the oxygen carrying Hb that is naturally present at birth and is then replaced by the adult form of hemoglobin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBBF5A77-7C27-24D1-E053-731AD00A1734","latestVersionIndicator":"Yes","beginDate":"2023-05-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-15","modifiedBy":"KUMMEROA","dateModified":"2023-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FBBF5A77-7C2A-24D1-E053-731AD00A1734","beginDate":"2023-05-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-15","modifiedBy":"KUMMEROA","dateModified":"2023-05-15","deletedIndicator":"No"},{"value":"Betibeglogene autotemcel (Zyntelgo)","valueDescription":null,"ValueMeaning":{"publicId":"13571197","version":"1","preferredName":"Betibeglogene Autotemcel","longName":"13571197v1.00","preferredDefinition":"A preparation of autologous, CD34-positive hematopoietic stem cells (HSCs) transduced ex vivo with the BB305 recombinant replication-defective, self-inactivating lentiviral vector encoding for an engineered form of human beta-globin (hemoglobin-beta, HBB) gene, beta-A-T87Q (b-A-T87Q) where the threonine at position 87 has been substituted with glutamine, with potential to restore beta-globin expression and function. Autologous CD34-positive stem cells are isolated from the patient's own bone marrow and the cells are transduced with the lentiviral vector. Upon re-infusion of betibeglogene autotemcel back into the patient, these cells express b-A-T87Q-globin, thereby allowing the body to make normal hemoglobin and thus normal, healthy red blood cells. Beta-globin, the beta-chain of the most common form of hemoglobin, is encoded by the HBB gene; mutations in this gene prevent normal beta-globin production and are associated with beta-thalassemia and sickle cell anemia. The b-A-T87Q form of beta-globin has increased antisickling activity compared to the wild type protein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Betibeglogene Autotemcel","conceptCode":"C123881","definition":"A preparation of autologous, CD34-positive hematopoietic stem cells (HSCs) transduced ex vivo with the BB305 recombinant replication-defective, self-inactivating lentiviral vector encoding for an engineered form of human beta-globin (hemoglobin-beta, HBB) gene, beta-A-T87Q (b-A-T87Q) where the threonine at position 87 has been substituted with glutamine, with potential to restore beta-globin expression and function. Autologous CD34-positive stem cells are isolated from the patient's own bone marrow and the cells are transduced with the lentiviral vector. Upon re-infusion of betibeglogene autotemcel back into the patient, these cells express b-A-T87Q-globin, thereby allowing the body to make normal hemoglobin and thus normal, healthy red blood cells. Beta-globin, the beta-chain of the most common form of hemoglobin, is encoded by the HBB gene; mutations in this gene prevent normal beta-globin production and are associated with beta-thalassemia and sickle cell anemia. The b-A-T87Q form of beta-globin has increased antisickling activity compared to the wild type protein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBBF5A77-7C28-24D1-E053-731AD00A1734","latestVersionIndicator":"Yes","beginDate":"2023-05-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-15","modifiedBy":"KUMMEROA","dateModified":"2023-05-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FBBF5A77-7C2B-24D1-E053-731AD00A1734","beginDate":"2023-05-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-15","modifiedBy":"KUMMEROA","dateModified":"2023-05-15","deletedIndicator":"No"},{"value":"Elivaldogene autotemcel (Skysona)","valueDescription":null,"ValueMeaning":{"publicId":"13571198","version":"1","preferredName":"Elivaldogene Autotemcel","longName":"13571198v1.00","preferredDefinition":"A gene replacement therapy agent composed of autologous cluster of differentiation 34 (CD34)-positive human hematopoietic stem cells (HSCs) transduced ex vivo with Lenti-D lentiviral vector (LVV), a replication-incompetent, self-inactivating LVV carrying ABCD1 complementary DNA (cDNA) that encodes normal adrenoleukodystrophy protein (ALD protein; ALDP), that can be used to treat early cerebral adrenoleukodystrophy (CALD). Upon administration, elivaldogene autotemcel engrafts in the bone marrow and differentiates into various cell types, including monocytes, that produce functional copies of the ABCD1 cDNA and thus functional ALDP. Functional ALDP degrades very long chain fatty acids (VLCFAs), which prevents accumulation of VLCFAs and may decrease or prevent further inflammation, demyelination and nerve damage. This slows the progression of neurologic dysfunction in patients with early, active cerebral adrenoleukodystrophy (CALD).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elivaldogene Autotemcel","conceptCode":"C171808","definition":"A gene replacement therapy agent composed of autologous cluster of differentiation 34 (CD34)-positive human hematopoietic stem cells (HSCs) transduced ex vivo with Lenti-D lentiviral vector (LVV), a replication-incompetent, self-inactivating LVV carrying ABCD1 complementary DNA (cDNA) that encodes normal adrenoleukodystrophy protein (ALD protein; ALDP), that can be used to treat early cerebral adrenoleukodystrophy (CALD). Upon administration, elivaldogene autotemcel engrafts in the bone marrow and differentiates into various cell types, including monocytes, that produce functional copies of the ABCD1 cDNA and thus functional ALDP. Functional ALDP degrades very long chain fatty acids (VLCFAs), which prevents accumulation of VLCFAs and may decrease or prevent further inflammation, demyelination and nerve damage. This slows the progression of neurologic dysfunction in patients with early, active cerebral adrenoleukodystrophy (CALD).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBBF5A77-7C29-24D1-E053-731AD00A1734","latestVersionIndicator":"Yes","beginDate":"2023-05-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-15","modifiedBy":"KUMMEROA","dateModified":"2023-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FBBF5A77-7C2C-24D1-E053-731AD00A1734","beginDate":"2023-05-15","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-05-15","modifiedBy":"KUMMEROA","dateModified":"2023-05-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7477454","version":"1","preferredName":"Gene Product Name","preferredDefinition":"A protein, RNA or a complex that contains proteins and/or RNA.:The words or language units by which a thing is known.","longName":"C26548:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gene Product","conceptCode":"C26548","definition":"A protein, RNA or a complex that contains proteins and/or RNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B25B88A6-86A4-5DF4-E053-4EBD850A31EC","latestVersionIndicator":"Yes","beginDate":"2020-10-23","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-23","modifiedBy":"ONEDATA","dateModified":"2020-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B25B88A6-86B5-5DF4-E053-4EBD850A31EC","latestVersionIndicator":"Yes","beginDate":"2020-10-23","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-23","modifiedBy":"KUMMEROA","dateModified":"2023-05-15","changeDescription":"Released. 01/28/2021 KMM","administrativeNotes":"2023.5.15 PVs added per ticket request CADSR0002428. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"PreTed_donor_gene_th_prod_nme","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the gene product tha","type":"Preferred Question Text","description":"What was the gene product that was administered?","url":null,"context":"NHLBI"},{"name":"Name of product","type":"Application Standard Question Text","description":"Name of product","url":null,"context":"NHLBI"},{"name":"Name of product","type":"Alternate Question Text","description":"Name of product","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B25B94AE-1613-37ED-E053-4EBD850A9063","latestVersionIndicator":"Yes","beginDate":"2020-10-23","endDate":null,"createdBy":"MALUMK","dateCreated":"2020-10-23","modifiedBy":"MALUMK","dateModified":"2021-03-18","changeDescription":"Released. 01/28/2021 KMM; 2020-12-8 AK Added RS. System generated def displayed as alt def. 10/23/2020 KMM. ALT name added for 2400r8. 03/18/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}